|Bid||170.25 x 900|
|Ask||170.70 x 900|
|Day's Range||169.44 - 171.48|
|52 Week Range||155.72 - 186.69|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||25.44|
|Forward Dividend & Yield||4.52 (2.59%)|
|Ex-Dividend Date||Aug 22, 2022|
|1y Target Est||N/A|
NEW BRUNSWICK, N.J., August 08, 2022--Johnson & Johnson (NYSE: JNJ) ("the Company") announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified.
NEW BRUNSWICK, N.J., August 02, 2022--Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7th. Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).
By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT Fiscal Year 2022 Operational & Financial Results Bioasis Technologies Inc. (OTC:BIOAF) filed fiscal year 2022 operational and financial reports with SEDAR on June 14, 2022 for the twelve-month period ending February 28, 2022. The most impactful event for Bioasis occurred after the end of the reporting period where the